Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Simmelink

Gastroenterology Charlotte, NC Medical Doctor

NPI 1295120061 CMS profile 1328689

1350 S Kings Dr Fl 3, Charlotte, NC 28207

Open in the dashboard

General payments

$8,095

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Simmelink of Charlotte, NC is reported in the CMS Open Payments database as having received $8,095 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,432 52
2024 General $1,849 62
2023 General $1,855 59
2022 General $1,546 89
2021 General $784 41
2020 General $12 1
2019 General $618 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Simmelink
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Andrew Simmelink were reported at $1,432. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Andrew Simmelink Gastroenterology median Middle half National median
2019 $618 $417 $126–$1,100 $163
2020 $12 $224 $74–$624 $114
2021 $784 $352 $106–$1,054 $132
2022 $1,546 $448 $129–$1,270 $149
2023 $1,855 $533 $150–$1,390 $160
2024 $1,849 $605 $160–$1,606 $164
2025 $1,432 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $4,376 164 payments
  2. Janssen Biotech, Inc. $631 27 payments
  3. Genzyme Corporation $427 9 payments
  4. Celgene Corporation $341 27 payments
  5. Pfizer Inc. $309 11 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $296 17 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $252 12 payments
  8. Ardelyx, Inc. $214 7 payments
  9. Gilead Sciences, Inc. $198 2 payments
  10. Novo Nordisk Inc $145 2 payments
  11. Other $906 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,054 307 payments
  2. Education $42 3 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $1,611 48 payments
  2. RINVOQ $1,542 64 payments
  3. LINZESS $549 33 payments
  4. HUMIRA $539 29 payments
  5. STELARA $445 20 payments
  6. ZEPOSIA $444 28 payments
  7. DUPIXENT $427 9 payments
  8. CREON $400 24 payments
  9. SKYRIZI Immunology $377 20 payments
  10. TREMFYA $289 8 payments
  11. Other $2,470 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

990

Median for Gastroenterology: 569

Drug cost

$80,382

Median for Gastroenterology: $104,976

Branded share of claims

44.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 17 $44,520
Linzess Linaclotide Brand 12 $13,196
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 37 $6,261
Omeprazole Generic 424 $4,467
Movantik Naloxegol Oxalate Brand 11 $4,248
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 248 $3,655
Pantoprazole Sodium Generic 71 $1,209
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 56 $858
Cholestyramine Cholestyramine (With Sugar) Brand 11 $492
Dicyclomine Hcl Generic 14 $388

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$103,373

Medicare's payments for the services billed

Medicare patients

457

Average age 74

Services billed

811

261 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 33%
Chronic kidney disease 32%
Ischemic heart disease 31%
Depression 28%
Heart failure 21%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $588
$588 — —
RINVOQ
  • AbbVie, Inc. $227
$227 — —
DUPIXENT
  • GENZYME CORPORATION $152
$152 — —
CREON
  • AbbVie, Inc. $116
$116 17 —
LINZESS
  • AbbVie, Inc. $115
$115 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record